12/23/2025
A nationwide cohort study in France compared maternal vaccination with the RSV prefusion F protein ( ) vaccine during pregnancy to passive infant immunization with for preventing RSV-related hospitalization.
Among over 42 000 matched infants, nirsevimab was associated with a lower risk of hospitalization for -associated lower respiratory tract infection, and lower risks of severe outcomes such as pediatric intensive care unit admission and the need for ventilatory support or oxygen.
https://ja.ma/45mgBp7